FTSE 350 Review 2019 

FTSE 350: Is big pharma ready for the dominance of genetics?

FTSE 350: Is big pharma ready for the dominance of genetics?

The pharmaceutical industry has always encountered questions about ethics – making profits from products developed to improve human life is certainly contentious. In 2019, there’s a new ethical challenge on the horizon, one that could either propel the global pharma industry into a glorious new era or spark further questions about pricing and margins: genetics.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now